Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

Metabolism: Clinical and Experimental

Volumn 52, Issue 7, 2003, Pages 908-915

  Glueck, C J ^a   Papanna, Ranganath ^a   Wang, Ping ^a   Goldenberg, Naila ^a   Sieve Smith, Luann ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PROTEIN; TRIACYLGLYCEROL;

ABNORMAL BODY BUILD; ADULT; AMENORRHEA AND OLIGOMENORRHEA; ARTERY THROMBOSIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CALORIC INTAKE; CARBOHYDRATE DIET; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; FAT INTAKE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DIET; RISK; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0042628161     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00104-5     Document Type: Article

References (50)

1. National Institutes of Health: Third Report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), NIH Publication 01-3670, 2001
2. Haffner SM, Valdez RA, Hazuda HP, et al: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
3. Isomaa B, Almgren P, Toorni T, et al: Cardiovascular morbidity and mortality associated with metabolic syndrome. Diabetes Care 24:683-689, 2001
4. Trovisan M, Liu J, Bahsas FB, et al: Syndrome X and mortality a population-based study. Am J Epidemiol 14B:958-966, 1998
5. Ford ES, Wayne HG, Dietz W II: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
6. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F-29F, 1999
7. Hansson L: Therapy of hypertension and metabolic syndrome: Today's standard and tomorrow's perspectives. Blood Press 20-22, 1998 (suppl 3)
8. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827, 2001
9. Riccardi G, Rivellese AA: Dietary treatment of the metabolic syndrome - The optimal diet. Br J Nutr S143-148, 2000 (suppl 1)
10. Pasquali R, Gambineri A, Anconetani B, et al: The natural history of the metabolic syndrome in young women in the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol 50:517-527, 1999
11. Glueck CJ, Wang P, Fontaine R, et al: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48:511-519, 1999
12. Knochenhauer ES, Key TJ, Kashar-Miller M, et al: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 83:3078-3082, 1998
13. Velazquez EM, Mendoza S, Hunter T, et al: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menes and pregnancy. Metabolism 43:647-654, 1994
14. Fleming R, Hopkinson ZE, Wallace RE, et al: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind, placebo-controlled trial. J Clin Endocrinol Metab 87:569-574, 2002
15. Kiddy DS, Hamilton-Fairley D, Bush A, et al: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105-111, 1992
16. Glueck CJ, Lang JE, Tracy T, et al: Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease in 239 hyperlipidemic patients. Metabolism 48:1427-1444, 1999
17. Glueck CJ, Wang P, Goldenberg N, et al: Pregnancy outcomes among women with polycystic ovary syndrome. Hum Reprod 17:2858-2864, 2002
18. Glueck CJ, Wang P, Kobayashi S, et al: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77:520-525, 2002
19. Kawadzki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: A rational approach, in Dunaif A, Givens JR, Haseltine F, et al (eds): Polycystic Ovary Syndrome. Cambridge, MA, Blackwell, 1992, pp 377-384
20. Ferriman D, Gallwey JD: Clinical Assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447, 1961
21. SAS/STAT Software. Changes and Enhancements Through Release 6.12. 1997. Cary NC, SAS Institute
22. Reaven G, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374-381, 1996
23. Lobo RA, Carmina E: The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132:989-993, 2000
24. Legro RS, Kunselman AR, Dodson WC, et al: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169, 1999
25. Talbott E, Guzick K, Clerici A, et al: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscl Thromb Vasc Biol 15:821-826, 1995
26. Talbott EO, Zborowski JV, Sutton-Tyrrell K, et al: Cardiovascular risk in women with polycystic ovary syndrome. Ob Gyn Clin N Am 28:111-133, 2001
27. Loucks T, Talbott ED, McHugh KP, et al: Do polycystic ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fert Steril 74:547-552, 2000
28. Parasidi G, Steinberg HO, Hempfling A, et al: Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415, 2001
29. Yarali H, Yildirir A, Aybar F, et al: Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76:511-516, 2001
30. Diamanti-Kandarakis E, Spina G, Kouli C, et al: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86:4666-4673, 2001
31. Guzick DS, Talbott EO, Sutton-Tyrell K, et al: Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol 174:1224-1229, 1996
32. Birdsall MA, Farquhar CM, White HD: Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Am J Obstet Gynecol 126:32-35, 1997
33. Dahlgren E, Janson PO, Johansson S, et al| Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:559-604, 1992b
34. Legro R, Urbanek M, Kunselman AR, et al: Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril 78:51-57, 2002
35. Korhonen S, Hippelsinen M, Niskanen L, et al: Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: A controlled, population-based study. Am J Obstet Gynecol 184:289-296, 2001
36. Eriksson KF, Lindgarde F: Prevention of type 2 non-insulin-dependent diabetes mellitus by detailed physical exercise: The 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
37. Pan XR, Li GW, Hu YM, et al: Effects of diet and exercise in prevention NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. Diabetes Care 20:537-544, 1997
38. Tuomilehto J, Lindstrom J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
39. Hu FB, Manson JE, Stampfer MJ, et al: Diet, lifetstyle, and the risk of type 2 diabetes in women. N Engl J Med 345:790-797, 2001
40. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
41. Freemark M, Bursey D: Effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyper-insulinemia and a family history of type 2 diabetes. Pediatrics 107:E55, 2001
42. Buchanan TA, Xiang AH, Peters RK, et al: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
43. Kay JP, Alemzadeh R, Langley G, et al: Beneficial effects of metforming in morbidly obese adolescents. Metabolism 50:1457-1461, 2001
44. Glueck CJ, Streicher P, Wang P: Treatment of polycystic ovary syndrome with insulin-lowering agents. Exp Opin Pharmacother 3:177-189, 2002
45. Perry RC, Fineberg N, McGill J, et al: The early diabetes intervention program (EDIP). Diabetes Care 24:465-471, 2001
46. Laaka H-M, Kaaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
47. Despres JP, Lamarche B, Mauriege P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
48. Folsom AR, Szklo M, Stevens J, et al: A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 209:935-942, 1997
49. Rubins HB, Robins SJ, Collins D, et al: Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the department of veteran's affairs high-density lipoprotein intervention trial (Va-HIT). Arch Intern Med 162:2597-2604, 2002
50. Kuusisto J, Lempiainen P, Mykkanen L, et al: Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24:1629-1633, 2001